Derivatives of 5-hydroxy-6-methyl-2-aminotetralin

Authors:
  • JCJoseph G. Cannon
    Joseph G. Cannon
  • DKDale L. Koble
    Dale L. Koble
  • JLJohn Paul Long
    John Paul Long
  • TVTurkiz Verimer
    Turkiz Verimer

Abstract
The title compounds were designed to provide semirigid congeners of m-tyramine in which the ring position ortho to the phenolic OH is blocked to metabolic hydroxylation. A sequence leading to a key synthetic intermediate, 5-methoxy-6-methyl-2-tetralone, was developed. In animal test models for dopamine-like effects, the title compounds demonstrated qualitative and quantitative differences from the isomeric 5-methyl-6-hydroxy-2-aminotetralins and from 5,6-dihydroxy-2-aminotetralins. Two of the compounds were potent in a cat cardioaccelerator nerve assay, which involves dopamine receptors.